Graves’ disease is an autoimmune disorder in which thyroid-stimulating immunoglobulins activate the thyroid’s TSH receptor, driving overproduction of thyroid hormone. It is the most common cause of hyperthyroidism in the United States, affecting roughly 1 in 200 adults, with a strong female predominance and typical onset between ages 30 and 50 according to the NIDDK. Untreated, the disease can produce serious cardiovascular complications including atrial fibrillation, heart failure, and the rare but life-threatening thyroid storm. Treatment options have changed little in 50 years but remain effective.
The Autoimmune Mechanism
Graves’ is caused by thyroid-stimulating immunoglobulins (TSI), also called TSH receptor antibodies (TRAb), that bind and activate the TSH receptor on thyroid follicular cells. The result is unregulated, sustained stimulation that drives both excessive hormone production and gland enlargement (goiter). The same antibodies — and possibly related immune mechanisms — cross-react with tissues behind the eye, producing the distinctive Graves’ ophthalmopathy.
Genetic susceptibility plays a major role. Family history is common. Triggers include stress, smoking, postpartum state, infection, and possibly excess iodine intake.
Hyperthyroid Symptoms
Symptoms reflect a hypermetabolic state. Unintended weight loss despite normal or increased appetite is classic — but a meaningful minority of patients gain weight, particularly older patients. Heat intolerance, sweating, palpitations, tremor, anxiety, irritability, and insomnia are common. Frequent loose stools, muscle weakness (especially proximal), and in women menstrual irregularities all occur.
Cardiovascular symptoms can dominate, especially in older patients. Atrial fibrillation affects up to 10 to 15 percent of hyperthyroid patients over 60. Tachycardia at rest and exercise intolerance are nearly universal. Per the Cleveland Clinic, untreated severe hyperthyroidism can produce heart failure even in young patients.
Graves’ Ophthalmopathy
Eye involvement affects 25 to 50 percent of patients to some degree, with severe disease in 3 to 5 percent. Symptoms include eyelid retraction, prominent eye appearance (proptosis), eye irritation, dryness, double vision, and in severe cases optic nerve compromise threatening vision.
Smoking dramatically worsens ophthalmopathy and is the single most modifiable risk factor. Radioactive iodine therapy can transiently worsen eye disease, particularly in smokers — short courses of corticosteroids around the time of treatment may be used in patients with active eye disease.
Teprotumumab, an IGF-1 receptor antagonist, was FDA-approved in 2020 for active moderate-to-severe Graves’ ophthalmopathy. It produces meaningful improvements in proptosis and double vision in trials but costs roughly $360,000 for a full 8-infusion course.
Diagnosis
TSH is suppressed (typically below 0.1 mIU/L) in overt hyperthyroidism, while free T4 and free T3 are elevated. Subclinical hyperthyroidism shows suppressed TSH with normal free T4 and free T3. TRAb is positive in over 95 percent of Graves’ patients and is the most specific test for the diagnosis.
Radioactive iodine uptake (RAIU) scan can distinguish Graves’ (high uptake, diffuse pattern) from toxic nodular goiter (high uptake, nodular pattern), thyroiditis (low uptake), and exogenous thyroid hormone use (low uptake). RAIU is not always needed when TRAb is clearly positive in a typical clinical picture.
Three Main Treatment Options
Antithyroid drugs — methimazole or propylthiouracil (PTU) — block thyroid hormone synthesis. Methimazole is preferred for most patients due to once-daily dosing, lower hepatotoxicity, and better remission rates. PTU is used in the first trimester of pregnancy (methimazole has small but real teratogenicity risk early) and in thyroid storm.
About 30 to 40 percent of patients achieve durable remission after 12 to 18 months of methimazole. Predictors of remission include smaller goiter, lower TRAb levels, and milder initial disease. Side effects include rash (5 to 10 percent), agranulocytosis (rare but serious — patients are warned to report fever and sore throat immediately), and hepatotoxicity.
Radioactive iodine (I-131) destroys thyroid tissue progressively over weeks to months. It is the most common definitive treatment in the US for non-pregnant adults. Most patients become hypothyroid within 6 to 12 months and require lifelong levothyroxine. Pregnancy must be deferred for 6 to 12 months. Active eye disease may worsen, which can be mitigated with steroid coverage.
Total or near-total thyroidectomy is the third option. It produces immediate cure and is preferred for patients with very large goiters, suspected malignancy in nodules, severe ophthalmopathy, or pregnancy considerations. Surgical complications include recurrent laryngeal nerve injury and hypoparathyroidism. Lifelong levothyroxine is needed afterward.
Beta-Blockers for Symptom Control
Propranolol or atenolol controls tachycardia, palpitations, tremor, and anxiety while definitive treatment takes effect. Beta-blockers do not lower thyroid hormone but block its peripheral effects. They are typically started immediately at diagnosis and tapered as thyroid function normalizes.
When to seek emergency care: Call 911 or go to the nearest emergency room if you experience high fever with severe sweating and confusion (possible thyroid storm), severe palpitations with chest pain or fainting, severe shortness of breath, sudden vision loss or severe eye pain (possible compressive optic neuropathy in Graves’ eye disease), severe agitation or psychosis, or signs of severe anemia or infection (possible agranulocytosis from antithyroid drugs — fever and sore throat warrant immediate evaluation). Thyroid storm is a medical emergency with substantial mortality even with treatment.
Thyroid Storm
Thyroid storm is the extreme end of hyperthyroidism — typically triggered by infection, surgery, trauma, or sudden withdrawal of antithyroid drugs in patients with poorly controlled Graves’. Symptoms include high fever (often above 103°F), tachycardia, atrial fibrillation, heart failure, severe agitation or delirium, vomiting, and diarrhea. Mortality remains 10 to 30 percent even with optimal ICU care.
Treatment combines high-dose antithyroid drugs, beta-blockers, corticosteroids, iodine (after antithyroid drugs are on board), supportive care, and treatment of the precipitating illness. Per PMC reviews, recognition matters because outcomes worsen with delay.
Pregnancy and Graves’ Disease
Hyperthyroidism in pregnancy raises risks of miscarriage, preterm birth, preeclampsia, low birth weight, and rarely fetal hyperthyroidism from maternal antibody crossover. PTU is preferred in the first trimester due to methimazole’s small teratogenic risk; methimazole is preferred in second and third trimesters due to PTU’s hepatotoxicity. Treatment aims for free T4 in the upper normal range using the lowest effective antithyroid drug dose.
TRAb levels at 22 to 26 weeks help estimate fetal risk of hyperthyroidism. High maternal TRAb levels can produce neonatal hyperthyroidism that needs treatment after birth, even if the mother is currently hypothyroid post-thyroidectomy. Coordination between endocrinology and high-risk obstetrics is standard.
Living With Graves’ Disease
Smoking cessation is the single most important lifestyle intervention. It reduces eye disease severity and progression. Iodine intake should be reasonable but not excessive — kelp supplements and high-iodine foods are generally avoided.
Most patients return to normal life within months of effective treatment. Patients on antithyroid drugs need TSH and T4 checks every 4 to 8 weeks during dose adjustment, then every 3 to 6 months. Post-RAI or post-thyroidectomy patients need long-term levothyroxine and periodic TSH monitoring. Our medical conditions overview covers chronic disease management broadly, and our Hashimoto’s guide covers the opposite autoimmune thyroid condition, which can occasionally develop after Graves’ treatment.
When to See a Doctor
Symptoms of unexplained weight loss, palpitations, heat intolerance, tremor, anxiety, or new eye prominence warrant TSH testing. Established Graves’ patients should have prompt evaluation for new fever and sore throat (agranulocytosis), worsening eye symptoms, severe palpitations, or pregnancy.
Endocrinology referral is standard for definitive treatment decisions. Ophthalmology should be involved for any active eye disease. Many doctors recommend smoking cessation counseling at every visit given the dramatic impact on eye disease.
Frequently Asked Questions
Is Graves’ disease life-threatening?
Most cases are not, with effective treatment. Rare but serious complications include thyroid storm, severe arrhythmias, and compressive optic neuropathy. Untreated severe hyperthyroidism over time can cause heart failure. With modern care, most patients have excellent outcomes.
Can Graves’ disease be cured?
Definitive treatments — radioactive iodine and total thyroidectomy — eliminate hyperthyroidism but produce hypothyroidism requiring lifelong levothyroxine. Antithyroid drugs produce sustained remission in 30 to 40 percent of patients after 12 to 18 months. Long-term remission off all therapy is possible but not guaranteed.
Will I need to take levothyroxine forever?
If treated with radioactive iodine or thyroidectomy, yes — almost all patients become permanently hypothyroid. If treated with antithyroid drugs and achieve remission, no levothyroxine is needed unless or until hyperthyroidism returns or hypothyroidism develops, which occurs in some patients over time.
Can stress cause Graves’ disease?
Stress does not directly cause Graves’ but is recognized as a possible trigger in genetically predisposed individuals, particularly major life stressors. The postpartum period is a known higher-risk window. Managing stress is reasonable but is not a substitute for definitive treatment.
The Bottom Line
Graves’ disease is treatable with three time-tested options — antithyroid drugs, radioactive iodine, and thyroidectomy — each with distinct tradeoffs. The choice depends on disease severity, eye involvement, pregnancy plans, patient preference, and local expertise. Smoking cessation matters more than many patients realize, particularly for those with eye involvement. Recognizing thyroid storm and agranulocytosis as medical emergencies, monitoring during pregnancy, and partnering with endocrinology for long-term management produce the best outcomes. Most patients live full normal lives after effective treatment, though many require lifelong attention to thyroid status.